Navigation Links
Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
Date:12/9/2008

ssed PFS and OS. Patients had a variety of cytogenetic abnormalities, including: 17p deletion (33 percent), 13q deletion (14 percent), trisomy 12 (12 percent), 11q deletion (20 percent) and 22 percent without any of the aforementioned abnormalities.

The ORR was 38 percent, with a 44 percent ORR in the 17p deletion group, 53 percent in patients with 13q deletion, 56 percent in the trisomy 12 group and 21 percent in the 11q deletion group. Patients without any of these abnormalities had an ORR of 27 percent.

Median PFS and OS for the whole group were 6.9 months and 30 months, respectively. In 17p deletion, patients' PFS was 7.1 months and OS was 19.1 months. A subanalysis of patients with 17p deletion who were also resistant to fludarabine (n=25), showed ORR of 28 percent and PFS and OS rates of 7.2 and 19.1 months, respectively. These results did not differ from those in fludarabine resistant patients categorized as having good risk cytogenetics.

Abstract #2095

CFAR, An Active Frontline Regimen for High-Risk Patients with CLL, Including Those with Del 17p

In this analysis, researchers evaluated Campath in combination with the standard treatment regimen known as FCR (fludarabine, cyclophosphamide and rituximab) as front-line therapy to a high-risk group of CLL patients.

Of the 60 patients intended for analysis in the CFAR group, 48 were evaluated for response and follow-up at the time of this interim analysis. Within this group of 48 patients, 28 percent (n=13) had 17p deletion identified by FISH analysis prior to treatment. Treatment with Campath resulted in an ORR of 94 percent and a CRR of 69 percent. In patients with 17p deletion, treatment with Campath resulted in an ORR of 77 percent and a CRR of 54 percent.

CFAR treatment regimen was associated with more myelosuppression and fewer p
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
3. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
4. Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
5. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
6. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
7. Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year
8. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Pomerantz LLP has filed a class action ... EDAP ) and certain of its officers.  ... Southern District of New York , ... class consisting of all persons or entities who purchased ... 2014, inclusive (the "Class Period"). This class action seeks to ...
(Date:8/29/2014)... Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... Global Healthcare Conference on Wednesday, September 10. ... Officer, will provide an update on the company, beginning ... Daylight Time).   A webcast of the ...
(Date:8/29/2014)... Research and Markets  has announced the addition of the ... to their offering. The Central Nervous System ... segments of pharmaceuticals industry. The numbers of CNS disorders have ... unable to meet the market requirements. There has been steady ... over the past two decades. The market for CNS therapies ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3US CNS Disorders Drug Pipeline Insight 2014 2
... Nov. 11, 2010 SRI International, an independent nonprofit ... Sc.D., has joined SRI International,s Center for Advanced Drug ... role, Dr. Perrone will head CADRE,s molecular diagnostic efforts, ... Dr. Perrone is an experienced marketing and business development ...
... SHENZHEN, China, Nov. 11, 2010 /PRNewswire-Asia-FirstCall/ -- Mindray Medical ... developer, manufacturer and marketer of medical devices worldwide, today ... Forum of Medicine International Trade Fair with Congress, to ... than 135,000 visitors from well over 100 countries are ...
Cached Medicine Technology:Joseph Perrone Joins SRI International to Direct Molecular Diagnostics and Rare and Neglected Diseases Group 2Joseph Perrone Joins SRI International to Direct Molecular Diagnostics and Rare and Neglected Diseases Group 3Joseph Perrone Joins SRI International to Direct Molecular Diagnostics and Rare and Neglected Diseases Group 4Mindray Medical to Exhibit at MEDICA 2010 in Dusseldorf, Germany from November 17- 20, 2010 2Mindray Medical to Exhibit at MEDICA 2010 in Dusseldorf, Germany from November 17- 20, 2010 3
(Date:8/29/2014)... As reported by WKMS.com in the article ... municipal court drug has come up with a new strategy ... as the presiding judge in a Southeastern Ohio municipal court ... a medicated treatment option that can literally prevent them from ... Vivitrol, which blocks receptors in the brain that would normally ...
(Date:8/29/2014)... by the Frederick News Post in the article Run For ... the Frederick County Drug Treatment Court has found a new way ... graduate, Korey Shorb, put together a race called Run For Recovery ... donate the proceeds of the event to the program he graduated ... graduated in 2008, admitted that he would probably be in jail ...
(Date:8/29/2014)... Healthpointe is proud to welcome to ... will be practicing out of Healthpointe’s newest office directly ... Healthpointe’s orthopedic team, Dr. Rodas is board-certified ... in occupational medicine. , Among Dr. Rodas’ many ... of Raytheon, the world-class defense and aerospace company. Additionally, ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Healthpointe ... Chapman University Physical Therapy students via Clinical Rotations. ... University will be shadowing Healthpointe providers and specialists ... them to develop clinical experience and learn professional ... students will gain insight into several patient care ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Pursuing its ... is set to unveil a stunning new design that ... company figures, the highly notable surrogacy platform has witnessed ... With over 13,000 visitors a month, the FindSurrogateMother.com community ... working toward one common goal — the precious gift ...
Breaking Medicine News(10 mins):Health News:Ohio Judge Pushes for Addiction Recovery Tool 2Health News:Ohio Judge Pushes for Addiction Recovery Tool 3Health News:Drug Court Grad Brings More Life to Drug Court Program 2Health News:Drug Court Grad Brings More Life to Drug Court Program 3Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3
... Executive says that almost 25 percent of cancer patients in ... the targeted time of two months. //The current data is ... ,The report said that just about 75 percent of all ... fell to 60 percent for bowel cancer patients and those ...
... Gripp and his team from DuPont Hospital studied genetic ... scientists found that the gene mutation occured in germline ... of the parents of the affected patients. The researchers ... Interscience. The researchers identified mutations in codon 12 or ...
... can be triggered by exposure to endotoxins in the ... Critical Care Medicine study. Humidifiers, pests, dust, pets, and ... according to the University of Iowa’s Dr. Peter S. ... homes selected to represent the demographic characteristics of the ...
... Centre International de Recherches Médicales de Franceville has identified ... of infection by the deadly Ebola virus // . ... are eaten in Central Africa by local Congolese and ... the infection is contracted through the eating habits of ...
... hope regarding the DNA vaccine trials conducted against the ... have already been completed among 40 HIV- negative // ... in the area of vaccine biology. It involves direct ... antigens into the human body. These vaccines precipitate an ...
... women who have had vaginal deliveries prior to their menopause ... their sisters who have never given birth // . In ... to their counterparts. ,Over 10 million people worldwide ... the other. It is a major health issue that ...
Cached Medicine News:Health News:DNA Vaccine Trials Against HIV Virus In Sweden Nurture Hope 2Health News:Urinary Stress Incontinence Not Related To Childbirth 2
... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
Medicine Products: